Back to top

FDMT Stock: Analyst Chardan Capital Maintains Buy Rating at $25 | FDMT Stock News

FDMT Stock: Analyst Chardan Capital Maintains Buy Rating at $25 | FDMT Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

4D Molecular Therapeutics, Inc. (FDMT)